MX380238B - Anticuerpos especificos para mmp9. - Google Patents
Anticuerpos especificos para mmp9.Info
- Publication number
- MX380238B MX380238B MX2017001959A MX2017001959A MX380238B MX 380238 B MX380238 B MX 380238B MX 2017001959 A MX2017001959 A MX 2017001959A MX 2017001959 A MX2017001959 A MX 2017001959A MX 380238 B MX380238 B MX 380238B
- Authority
- MX
- Mexico
- Prior art keywords
- mmp9
- specific antibodies
- fragment
- useful
- chain variable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14180765.1A EP2985296A1 (en) | 2014-08-13 | 2014-08-13 | Antibodies specific for MMP9 |
| PCT/EP2015/068645 WO2016023979A1 (en) | 2014-08-13 | 2015-08-13 | Antibodies specific for mmp9 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017001959A MX2017001959A (es) | 2017-05-04 |
| MX380238B true MX380238B (es) | 2025-03-12 |
Family
ID=51301193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001959A MX380238B (es) | 2014-08-13 | 2015-08-13 | Anticuerpos especificos para mmp9. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10364296B2 (enExample) |
| EP (2) | EP2985296A1 (enExample) |
| JP (1) | JP6856523B2 (enExample) |
| KR (1) | KR20170041222A (enExample) |
| CN (1) | CN106573984A (enExample) |
| AU (1) | AU2015303183B2 (enExample) |
| BR (1) | BR112017002703A2 (enExample) |
| CA (1) | CA2956986A1 (enExample) |
| ES (1) | ES2784271T3 (enExample) |
| MX (1) | MX380238B (enExample) |
| PL (1) | PL3180362T3 (enExample) |
| RU (1) | RU2714043C2 (enExample) |
| WO (1) | WO2016023979A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019513737A (ja) | 2016-04-08 | 2019-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法 |
| EP3555138A1 (en) | 2016-12-16 | 2019-10-23 | Université de Bordeaux | Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder |
| CN110997001A (zh) * | 2017-06-02 | 2020-04-10 | 默克专利股份有限公司 | Mmp13结合免疫球蛋白 |
| US20200124604A1 (en) * | 2017-06-30 | 2020-04-23 | National Institutes Of Biomedical Innovation, Health And Nutrition | Biomarker for detecting colorectal cancer |
| KR102657653B1 (ko) * | 2017-07-18 | 2024-04-16 | 다이이찌 산쿄 가부시키가이샤 | 활성형 mmp-9 결합 펩티드 |
| EP3723770A4 (en) | 2017-12-13 | 2021-11-24 | North Carolina State University | COMPOSITIONS INCLUDING CHEMOTHERAPEUTIC AGENTS AND CHECKPOINT INHIBITORS AND METHODS OF USE |
| DK3743534T3 (da) * | 2018-01-22 | 2022-06-20 | Liquid Biopsy Res Llc | Fremgangsmåde til påvisning af coloncancer og behandlingsovervågning |
| CN108277214B (zh) * | 2018-02-23 | 2021-07-06 | 广东医科大学 | 一种应激磷酸化抗原多肽、抗体、制备方法以及应用 |
| WO2020237092A2 (en) * | 2019-05-21 | 2020-11-26 | The Regents Of The University Of California | Mmp-9 antibodies and methods of use thereof |
| CN110885375B (zh) * | 2019-12-20 | 2021-07-02 | 南京融捷康生物科技有限公司 | 特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用 |
| WO2023278491A1 (en) * | 2021-06-28 | 2023-01-05 | Releviate, Llc | Mmp-9 antibodies and uses thereof |
| JP2023021745A (ja) * | 2021-08-02 | 2023-02-14 | 学校法人東京薬科大学 | がん転移抑制のための医薬組成物 |
| CN117327186B (zh) * | 2023-07-12 | 2024-03-12 | 北京达成生物科技有限公司 | 结合mmp3蛋白的双特异性抗体及其用途 |
| EP4788430A1 (en) | 2023-10-05 | 2026-08-12 | Ashibio, Inc. | Methods and compositions for treating mmp-9 mediated disorders |
| CN117264069B (zh) * | 2023-11-23 | 2024-01-26 | 再少年(北京)生物科技有限公司 | 一种促进皮肤组织再生的工程化外泌体的制备方法及其应用 |
| CN117820488B (zh) * | 2024-01-09 | 2024-10-01 | 首都医科大学附属北京朝阳医院 | 特异性针对mmp-9的抗体对、生物材料及其应用 |
| CN117964771B (zh) * | 2024-04-02 | 2024-06-21 | 智泽童康(广州)生物科技有限公司 | 一种特异性结合mmp7的抗体、mmp7检测试剂及其应用 |
| WO2026076260A1 (en) | 2024-10-03 | 2026-04-09 | Ashibio, Inc. | Methods and compositions for mmp-9 inhibition for use with non-genetic heterotopic ossification disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002235692A1 (en) * | 2001-02-23 | 2002-09-04 | Biophage Inc. | Methods and compositions for preventing and treating neutrophil-mediated diseases |
| GB0516069D0 (en) | 2005-08-04 | 2005-09-14 | Imp College Innovations Ltd | Pharmaceutical and use thereof |
| EP2155691B1 (en) * | 2007-02-23 | 2016-01-13 | Yeda Research and Development Co. Ltd. | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
| JP2011517662A (ja) * | 2008-03-03 | 2011-06-16 | ダイアックス コーポレーション | メタロプロテアーゼ９結合タンパク質 |
| US8013125B2 (en) | 2008-03-03 | 2011-09-06 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| WO2010045388A2 (en) * | 2008-10-14 | 2010-04-22 | Dyax Corp. | Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis |
| WO2011028883A2 (en) * | 2009-09-03 | 2011-03-10 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| WO2012027721A2 (en) * | 2010-08-27 | 2012-03-01 | Gilead Biologics, Inc | Antibodies to matrix metalloproteinase 9 |
| MD20140108A2 (ro) * | 2012-02-29 | 2015-03-31 | Gilead Biologics, Inc. | Anticorpi împotriva metaloproteinazei 9 matriciale |
| SG11201405305PA (en) | 2012-02-29 | 2014-09-26 | Gilead Biologics Inc | Antibodies to matrix metalloproteinase 9 |
-
2014
- 2014-08-13 EP EP14180765.1A patent/EP2985296A1/en not_active Withdrawn
-
2015
- 2015-08-13 PL PL15749818T patent/PL3180362T3/pl unknown
- 2015-08-13 AU AU2015303183A patent/AU2015303183B2/en not_active Ceased
- 2015-08-13 BR BR112017002703-8A patent/BR112017002703A2/pt not_active IP Right Cessation
- 2015-08-13 CN CN201580043394.1A patent/CN106573984A/zh active Pending
- 2015-08-13 CA CA2956986A patent/CA2956986A1/en not_active Abandoned
- 2015-08-13 ES ES15749818T patent/ES2784271T3/es active Active
- 2015-08-13 RU RU2017107773A patent/RU2714043C2/ru active
- 2015-08-13 WO PCT/EP2015/068645 patent/WO2016023979A1/en not_active Ceased
- 2015-08-13 JP JP2017508053A patent/JP6856523B2/ja not_active Expired - Fee Related
- 2015-08-13 EP EP15749818.9A patent/EP3180362B1/en active Active
- 2015-08-13 US US15/503,447 patent/US10364296B2/en not_active Expired - Fee Related
- 2015-08-13 KR KR1020177004988A patent/KR20170041222A/ko not_active Ceased
- 2015-08-13 MX MX2017001959A patent/MX380238B/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20170233495A1 (en) | 2017-08-17 |
| BR112017002703A2 (pt) | 2018-02-27 |
| JP6856523B2 (ja) | 2021-04-07 |
| JP2017532005A (ja) | 2017-11-02 |
| AU2015303183A1 (en) | 2017-02-16 |
| ES2784271T3 (es) | 2020-09-23 |
| CN106573984A (zh) | 2017-04-19 |
| WO2016023979A1 (en) | 2016-02-18 |
| EP3180362A1 (en) | 2017-06-21 |
| PL3180362T3 (pl) | 2020-06-15 |
| EP3180362B1 (en) | 2020-02-05 |
| AU2015303183B2 (en) | 2021-01-28 |
| MX2017001959A (es) | 2017-05-04 |
| RU2714043C2 (ru) | 2020-02-11 |
| CA2956986A1 (en) | 2016-02-18 |
| KR20170041222A (ko) | 2017-04-14 |
| US10364296B2 (en) | 2019-07-30 |
| RU2017107773A3 (enExample) | 2018-09-13 |
| EP2985296A1 (en) | 2016-02-17 |
| RU2017107773A (ru) | 2018-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017001959A (es) | Anticuerpos especificos para mmp9. | |
| CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
| CY1121542T1 (el) | Μορια αντισωματων σε pd-1 και χρηση αυτων | |
| CY1125327T1 (el) | Anti-pd-1 αντισωματα και συνθεσεις | |
| CY1125267T1 (el) | Antiσωmata eiδiκως σynδeonta pd-1 kai xphσeiς aytωn | |
| JOP20200312A1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| MX2020000960A (es) | Anticuerpos anti-tigit. | |
| SA522431756B1 (ar) | Tigit أجسام مضادة لـ | |
| EA202091540A1 (ru) | Антитела к lilrb2 | |
| EA201790834A1 (ru) | Молекулы антител к pd-l1 и их применение | |
| MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
| GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
| EA201990594A1 (ru) | Анти-tim-3 антитела и их применение | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
| EA201792467A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
| MX375032B (es) | Proteínas de unión y métodos para utilizarlas. | |
| EA202091315A2 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
| EA201692394A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
| MX385868B (es) | Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias. | |
| EA201792220A1 (ru) | Опосредуемая антителом нейтрализация вируса чикунгунья | |
| CY1124445T1 (el) | Αντισωματα αντι-ccl17 | |
| PH12019500342A1 (en) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 | |
| MX2017007747A (es) | Anticuerpos para il-17c. |